# AHDC1

## Overview
The AHDC1 gene encodes the AT-hook DNA binding motif containing 1 protein, which is characterized by its AT-hook DNA-binding motifs. These motifs enable the protein to interact with AT-rich regions of DNA, suggesting its involvement in chromatin organization and transcriptional regulation. AHDC1 is primarily localized in the nucleus, where it plays a crucial role in maintaining nuclear structure and modulating gene expression, particularly in neural tissues. The protein's interactions with other nuclear proteins involved in epigenetic regulation underscore its potential significance in neural development and function. Mutations in the AHDC1 gene are linked to Xia-Gibbs Syndrome and other neurodevelopmental disorders, highlighting its importance in normal neurological development (Wang2020Microdeletion; Khayat2021Phenotypic; Khayat2021AHDC1).

## Structure
The AHDC1 gene encodes a protein characterized by the presence of an AT-hook motif, a small DNA-binding domain that interacts with the minor groove of AT-rich DNA sequences. This motif is crucial for the protein's role in DNA binding. The primary structure of the AHDC1 protein consists of a specific sequence of amino acids that determine its function and interactions. The secondary structure may include elements such as alpha helices and beta sheets, which contribute to the protein's stability and shape. The tertiary structure refers to the overall three-dimensional conformation of the protein, which is essential for its biological activity. While the quaternary structure involves the assembly of multiple protein subunits, it is not specified whether AHDC1 forms such complexes. Post-translational modifications and splice variant isoforms can influence the protein's function, potentially altering its interaction with DNA and other proteins. These structural features collectively enable AHDC1 to perform its role in DNA binding and regulation, although specific details on these aspects are not fully detailed in the available context.

## Function
The AHDC1 gene encodes a protein that plays a significant role in DNA binding and regulation of gene expression, primarily within the nucleus of cells. The protein contains AT-hook DNA-binding motifs, which enable it to bind to AT-rich regions of DNA, suggesting a role in chromatin organization and transcriptional regulation (Wang2020Microdeletion; Khayat2021Phenotypic). AHDC1 is associated with heterochromatin-rich sites, indicating its involvement in chromatin remodeling and nuclear structure maintenance (Khayat2021Phenotypic).

In healthy human cells, AHDC1 is expressed in the nucleoli, nucleoplasm, and throughout the nucleus, suggesting its involvement in various nuclear processes, particularly in the brain where its expression is elevated (Khayat2021Phenotypic). The protein's interaction with nuclear proteins involved in epigenetic regulation highlights its potential role in neural development and function (Wang2020Microdeletion). AHDC1's function in healthy cells likely involves modulating gene expression patterns critical for normal cellular processes such as development and differentiation (Wang2020Microdeletion). The gene's structure, with a single coding exon, allows for the production of a protein that may form multimeric structures or large aggregations, further influencing its functional role in the cell (Khayat2021Phenotypic).

## Clinical Significance
Mutations in the AHDC1 gene are associated with Xia-Gibbs Syndrome (XGS), a rare genetic disorder characterized by intellectual disability, developmental delay, and distinctive facial features. De novo truncating mutations in AHDC1 are a primary cause of XGS, leading to loss-of-function alleles that disrupt normal protein interactions crucial for brain development (Wang2020Microdeletion; Khayat2021AHDC1). These mutations can result in a range of neurodevelopmental issues, including hypotonia, sleep apnea, and expressive language delay (Yang2015De; Xia2014De).

The clinical significance of AHDC1 mutations extends to other neurodevelopmental disorders. Truncating variants have been linked to severe intellectual disability, autism spectrum disorder, and various neurological problems such as seizures and ataxia (Khayat2021Phenotypic; Yang2015De). Missense mutations in AHDC1 may also contribute to phenotypic variability, potentially causing gain-of-function effects or different disease traits (Khayat2021AHDC1).

Alterations in AHDC1 expression, such as deletions or duplications, can also lead to clinical manifestations similar to XGS, suggesting a haploinsufficiency mechanism (Wang2020Microdeletion). These genetic changes highlight the critical role of AHDC1 in normal neurological development and function.

## Interactions
The AHDC1 protein is known to interact with the Tip-1 protein, a hub protein involved in pathways linked to cancer progression. This interaction was identified using a yeast two-hybrid screen, which revealed that AHDC1 contains a C-terminal PDZ binding domain crucial for its binding to Tip-1. The interaction was confirmed through yeast mating assays, which demonstrated that AHDC1 mutants lacking the PDZ binding motif did not bind to Tip-1, highlighting the importance of this domain for the interaction (Shalaby2011Identification).

Immunofluorescent imaging studies in HPV16 E6 expressing human C33A cervical carcinoma cells suggested potential co-localization of AHDC1 and Tip-1, indicating that these proteins may interact within cellular environments (Shalaby2011Identification). The study suggests that the interaction between AHDC1 and Tip-1 could provide insights into novel functions and roles in cellular processes, particularly those related to carcinogenesis (Shalaby2011Identification). This interaction underscores the potential significance of AHDC1 in cancer-related pathways, mediated through its binding with Tip-1.


## References


[1. (Khayat2021AHDC1) Michael M. Khayat, Jianhong Hu, Yunyun Jiang, He Li, Varuna Chander, Moez Dawood, Adam W. Hansen, Shoudong Li, Jennifer Friedman, Laura Cross, Emilia K. Bijlsma, Claudia A.L. Ruivenkamp, Francis H. Sansbury, Jeffrey W. Innis, Jessica Omark O’Shea, Qingchang Meng, Jill A. Rosenfeld, Kirsty McWalter, Michael F. Wangler, James R. Lupski, Jennifer E. Posey, David Murdock, and Richard A. Gibbs. Ahdc1 missense mutations in xia-gibbs syndrome. Human Genetics and Genomics Advances, 2(4):100049, October 2021. URL: http://dx.doi.org/10.1016/j.xhgg.2021.100049, doi:10.1016/j.xhgg.2021.100049. This article has 6 citations.](https://doi.org/10.1016/j.xhgg.2021.100049)

[2. (Khayat2021Phenotypic) Michael M. Khayat, He Li, Varuna Chander, Jianhong Hu, Adam W. Hansen, Shoudong Li, Josh Traynelis, Hua Shen, George Weissenberger, Fabio Stossi, Hannah L. Johnson, James R. Lupski, Jennifer E. Posey, Aniko Sabo, Qingchang Meng, David R. Murdock, Michael Wangler, and Richard A. Gibbs. Phenotypic and protein localization heterogeneity associated with ahdc1 pathogenic protein‐truncating alleles in xia–gibbs syndrome. Human Mutation, 42(5):577–591, March 2021. URL: http://dx.doi.org/10.1002/humu.24190, doi:10.1002/humu.24190. This article has 14 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.24190)

[3. (Xia2014De) Fan Xia, Matthew N. Bainbridge, Tiong Yang Tan, Michael F. Wangler, Angela E. Scheuerle, Elaine H. Zackai, Margaret H. Harr, V. Reid Sutton, Roopa L. Nalam, Wenmiao Zhu, Margot Nash, Monique M. Ryan, Joy Yaplito-Lee, Jill V. Hunter, Matthew A. Deardorff, Samantha J. Penney, Arthur L. Beaudet, Sharon E. Plon, Eric A. Boerwinkle, James R. Lupski, Christine M. Eng, Donna M. Muzny, Yaping Yang, and Richard A. Gibbs. De novo truncating mutations in ahdc1 in individuals with syndromic expressive language delay, hypotonia, and sleep apnea. The American Journal of Human Genetics, 94(5):784–789, May 2014. URL: http://dx.doi.org/10.1016/j.ajhg.2014.04.006, doi:10.1016/j.ajhg.2014.04.006. This article has 51 citations.](https://doi.org/10.1016/j.ajhg.2014.04.006)

[4. (Wang2020Microdeletion) Qingming Wang, Xiaoling Huang, Yanhui Liu, Qian Peng, Yuqiong Zhang, Jianxin Liu, and Haiming Yuan. Microdeletion and microduplication of 1p36.11p35.3 involving ahdc1 contribute to neurodevelopmental disorder. European Journal of Medical Genetics, 63(1):103611, January 2020. URL: http://dx.doi.org/10.1016/j.ejmg.2019.01.001, doi:10.1016/j.ejmg.2019.01.001. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ejmg.2019.01.001)

[5. (Shalaby2011Identification) Manal Aly Shalaby, Lynne Hampson, Anthony Oliver, and Ian Hampson. Identification of plexind1 and ahdc1 as a putative interactors for tip-1 protein. Genes &amp; Genomics, 33(4):399–405, August 2011. URL: http://dx.doi.org/10.1007/s13258-011-0033-1, doi:10.1007/s13258-011-0033-1. This article has 7 citations.](https://doi.org/10.1007/s13258-011-0033-1)

[6. (Yang2015De) Hui Yang, Ganka Douglas, Kristin G. Monaghan, Kyle Retterer, Megan T. Cho, Luis F. Escobar, Megan E. Tucker, Joan Stoler, Lance H. Rodan, Diane Stein, Warren Marks, Gregory M. Enns, Julia Platt, Rachel Cox, Patricia G. Wheeler, Carrie Crain, Amy Calhoun, Rebecca Tryon, Gabriele Richard, Patrik Vitazka, and Wendy K. Chung. De novo truncating variants in the ahdc1 gene encoding the at-hook dna-binding motif-containing protein 1 are associated with intellectual disability and developmental delay. Molecular Case Studies, 1(1):a000562, September 2015. URL: http://dx.doi.org/10.1101/mcs.a000562, doi:10.1101/mcs.a000562. This article has 26 citations.](https://doi.org/10.1101/mcs.a000562)